Osteoporosis – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23023IDB-L5

Select Item

Empower your strategies with our Osteoporosis – Drugs In Development, 2024 report and make more profitable business decisions.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, and a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

The Osteoporosis drugs in development market research report provide comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Osteoporosis
Key Targets
· Tumor Necrosis Factor Ligand Superfamily Member 11; Parathyroid Hormone Receptor; Sclerostin; Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor; Estrogen Receptor; Peroxisome Proliferator Activated Receptor Gamma; Vitamin D Receptor; Vitamin D3 Receptor; Leucine Rich Repeat Containing G Protein Coupled Receptor 4; and Farnesyl Pyrophosphate Synthase
Key Mechanisms of Action
· Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor; Parathyroid Hormone Receptor Agonist; Sclerostin Inhibitor; Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist; Vitamin D Receptor Agonist; Estrogen Receptor Agonist; Peroxisome Proliferator Activated Receptor Gamma Antagonist; Vitamin D3 Receptor Agonist; Estrogen Receptor Antagonist; and Farnesyl Pyrophosphate Synthase Inhibitor
Key Routes of Administration
· Subcutaneous; Oral; Parenteral; Intravenous; Transdermal; Topical; Inhalational; and Nasal
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Recombinant Peptide; Recombinant Protein; Biologic; Synthetic Peptide; Cell Therapy; Peptide; Fusion Protein; and Gene Therapy
Major Companies
· University of Wisconsin Madison; University of Toledo; Affilogic SAS; Lead Discovery Center GmbH; Max Biopharma Inc; GENUONE Sciences Inc; Galapagos NV; Jiangsu Hengrui Medicine Co Ltd; Huons Global Co Ltd; and Amgen Inc

Scope

  • Therapeutics in Development: Covering 182 molecules, with 152 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Osteoporosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Osteoporosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Osteoporosis treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Ablynx NV
Aclaris Therapeutics Inc
AdAlta Ltd
Addpharma Inc
Aerami Therapeutics Inc
Affilogic SAS
AgeX Therapeutics Inc
Airsea (Taizhou) Pharmaceutical Ltd
AlphaMab Co Ltd
Alvotech SA
Amgen Inc
Angitia Biopharmaceuticals
Aryogen Pharmed Co
Augusta University
Aurobindo Pharma Ltd
aVaxziPen Limited
Aveta Biomics Inc
Bainan Biotech ApS
Baiya Phytopharm Co Ltd
Beijing Health Guard Biotechnology Inc
Beijing Northland Biotech Co Ltd
Beryl Therapeutics Inc
Better Life Pharmaceuticals Inc
Biocon Ltd
Bone Biologics Corp
Carpe Vitae Pharmaceuticals Pty Ltd
Cellatoz Therapeutics Inc
Celltrion Inc
Central Drug Research Institute
China NT Pharma Group Co Ltd
ChoDang Pharm Co Ltd
Cinnagen Co
Citragen Pharmaceuticals Inc
CK Regeon Inc
Clayton Biotechnologies Inc
Clonz Biotech Pvt Ltd
Columbia University Medical Center
Corium Inc
CSPC Pharmaceutical Group Ltd
Curexsys GmbH
Daewoong Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
Eden Biologics Inc
Eli Lilly and Co
Endoceutics Inc
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epygen Biotech Pvt Ltd
Ewha Womans University
Fresenius Kabi SwissBioSim GmbH
Galapagos NV
Gedeon Richter Plc
Genor BioPharma Co Ltd
GENUONE Sciences Inc
GlycoNex Inc
GPN Therapeutics Inc
Haoma Medica Ltd
Helixmith Co Ltd
Histide AG
HK inno.N Corp
HNB Therapeutics LLC
Hualan Biological Engineering Inc
Huons Global Co Ltd
Icahn School of Medicine at Mount Sinai
Indiana University School of Medicine
InnoPharmaScreen Inc
Innopharmax Inc
iProgen Biotech Inc
Ipsen SA
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Pacific Meinuoke Bio-Pharmarceutical Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Keros Therapeutics Inc
Kyoto Pharmaceutical Industries Ltd
Lactocore Inc
Lead Discovery Center GmbH
Lexeo Therapeutics Inc
Link Biologics Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
Mabxience Holding SL
Max Biopharma Inc
Max Delbruck Center for Molecular Medicine
Medispan
Merck & Co Inc
Mesentech Inc
Mezomax Inc
Minapharm Pharmaceuticals
Monash University
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
NextCure Inc
NovMetaPharma Co Ltd
Omeros Corp
Oncosimis Biotech Pvt Ltd
Ortho Regenics Pvt Ltd
Osaka University
OssiFi Inc
Paras Biopharmaceuticals Finland Oy
PhytoHealth Corp
Prestige BioPharma Ltd
PRG S&Tech Inc
Qualix DoT sl
Radius Health Inc
Rani Therapeutics LLC
Regenerative Arthritis & Bone Medicine Inc
Reliance Life Sciences Pvt Ltd
Saarland University
Samsung Bioepis Co Ltd
Sandoz Group AG
Shaanxi Micot Technology Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shanghai Braegen Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Stony Brook University
Strides Pharma Science Ltd
Surrozen Inc
Suzhou Stainwei Biotech Inc
Taithera Inc
Takeda Pharmaceutical Co Ltd
Tempest Therapeutics Inc
Teva Pharmaceutical Industries Ltd
The National Institute for Biotechnology in the Negev Ltd
The Scripps Research Institute
The United Laboratories International Holdings Ltd
Transcenta Holding Ltd
Tritech Biopharmaceuticals Co Ltd
TSH Biopharm Corporation Ltd
Tulane University
Uni-Bio Science Group Ltd
Univeristy of Zaragoza
University of California San Diego
University of Hong Kong
University of Montpellier
University of Toledo
University of Wisconsin Madison
Vibe Pharmaceuticals LLC
Victoria University of Wellington
Vidasym Inc
Viking Therapeutics Inc
Wonkwang University
Wuxi Hebang Biotechnology Co Ltd
Yonsei University
Yooyoung Pharm Co Ltd
Zosano Pharma Corp
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Osteoporosis reports
Pharmaceuticals
New
Chronic Kidney Disease in Major Markets: Disease Management, Epidemiology, Pipeline…
$17,995 | August 2026
Pharmaceuticals
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Pharmaceuticals
New
Pharmaceutical Drug Development Annual Review 2025
$1,200 | August 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteoporosis – Drugs In Development, 2024 in real time.

  • Access a live Osteoporosis – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more